So sánh phương pháp

	Chỉ số chất lượng cuộc sống da liễu ở trẻ em (cDLQI)	MelasQoL (Thang đo Chất lượng Cuộc sống trong Bệnh Rối loạn Sắc tố Da Mặt)	POEM (Thước đo Eczema Định hướng Bệnh nhân)
Lĩnh vực	Da liễu học	Da liễu học	Da liễu học
Họ	Process / pipeline	Process / pipeline	Process / pipeline
Năm ra đời	1995	2006	2004
Người khởi xướng	Lewis-Jones MS, Finlay AY	Cestari TF, Hexsel D	Charman CR, Venn AJ, Williams HC
Loại	Self-report (parent or child proxy)	Self-report	Self-report
Công trình gốc	Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (cDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942-949.	Cestari TF, Hexsel D, Brandt FS, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL. Br J Dermatol. 2006;156(Suppl 3):13-20.	Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513-1519.
Tên gọi khác	cDLQI, Pediatric DLQI	Melasma-QoL	POEM Score
Liên quan	3	3	2
Tóm tắt	The Children's Dermatology Life Quality Index (cDLQI) is a pediatric-adapted version of the adult DLQI, measuring the impact of skin disease on quality of life in children and adolescents aged 4–16 years. Developed by Lewis-Jones and Finlay in 1995, it uses child-friendly language and addresses domains relevant to childhood (school, leisure, friendships, clothing) rather than work and adult relationships. cDLQI is the standard quality-of-life measure in pediatric dermatology trials and clinical practice.	MelasQoL is a disease-specific, patient-administered quality-of-life measure designed to assess the psychosocial burden of melasma, a common chronic disorder of symmetric facial hyperpigmentation. Developed by Cestari and colleagues in 2006, it captures the unique emotional and social impacts of a predominantly cosmetic condition that disproportionately affects women of color. MelasQoL is essential in clinical trials and observational studies of melasma treatments to ensure that efficacy encompasses meaningful quality-of-life outcomes.	The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week. Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care.